Jefferies downgraded Opko Health (OPK) to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko’s drug pipeline has potential, but is still early with a need for clarity on catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPK: